HighTower Advisors LLC Buys 47,680 Shares of Orthofix Medical Inc. (NASDAQ:OFIX)

HighTower Advisors LLC grew its holdings in Orthofix Medical Inc. (NASDAQ:OFIX - Free Report) by 114.9% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 89,183 shares of the medical device company's stock after purchasing an additional 47,680 shares during the period. HighTower Advisors LLC owned approximately 0.23% of Orthofix Medical worth $1,393,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. HighVista Strategies LLC acquired a new stake in shares of Orthofix Medical during the 3rd quarter valued at $1,689,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Orthofix Medical during the 3rd quarter valued at $270,000. Verition Fund Management LLC boosted its holdings in shares of Orthofix Medical by 14.9% during the 3rd quarter. Verition Fund Management LLC now owns 31,704 shares of the medical device company's stock valued at $495,000 after acquiring an additional 4,112 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Orthofix Medical by 5.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,994 shares of the medical device company's stock worth $156,000 after buying an additional 559 shares during the period. Finally, BNP Paribas Financial Markets lifted its holdings in Orthofix Medical by 37.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 34,758 shares of the medical device company's stock worth $543,000 after buying an additional 9,456 shares during the period. Institutional investors own 89.76% of the company's stock.

Analysts Set New Price Targets

Several research analysts have commented on OFIX shares. Stifel Nicolaus raised Orthofix Medical from a "hold" rating to a "buy" rating and lifted their target price for the stock from $18.00 to $24.00 in a report on Friday, November 8th. Roth Mkm reaffirmed a "buy" rating and set a $22.00 target price (up from $20.00) on shares of Orthofix Medical in a report on Friday, November 8th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $23.00.

Orthofix Medical Trading Up 0.3 %

Shares of NASDAQ:OFIX traded up $0.05 during midday trading on Monday, reaching $18.01. The company's stock had a trading volume of 180,586 shares, compared to its average volume of 321,746. The firm has a market capitalization of $688.16 million, a price-to-earnings ratio of -5.75 and a beta of 1.09. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.11 and a current ratio of 2.39. The firm has a 50 day moving average price of $17.61 and a two-hundred day moving average price of $16.11. Orthofix Medical Inc. has a fifty-two week low of $12.05 and a fifty-two week high of $20.73.

Orthofix Medical Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.